The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.

This article provides an overview of the results of the MATRIX study. Subsequent articles will provide more detailed results of other findings in this study. Overall, this study found that OXY-TDS administration resulted in improvement in HRQoL, with the medication having its greatest effect on the impact of incontinence, severity of symptoms, and role limitations. OXY-TDS was well tolerated, with a low prevalence of anticholinergic adverse events noted. The next article will focus on results in populations older than 65 years and in those older than 80 years.